Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study

Zhigang Wang(Dalian Medical University), Erwin Dreesen(KU Leuven), Séverine Vermeire(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), João Sabino(KU Leuven)
Clinical Gastroenterology and Hepatology
January 12, 2023
10.1016/j.cgh.2023.01.004
Cited by 21

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k